Cempra tanks on ‘positive’ Phase III for pneumonia antibiotic

Damian Garde

's in-development treatment for bacterial measured up to the now-generic moxifloxacin in a III study, but the combination of alarming safety signals and a trial supply issue soured investors on the drug's future.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS